Back to Search Start Over

c-MYC Asn11Ser is associated with increased risk for familial breast cancer.

Authors :
Wirtenberger M
Hemminki K
Försti A
Klaes R
Schmutzler RK
Grzybowska E
Bermejo JL
Wappenschmidt B
Bugert P
Butkiewicz D
Pamula J
Pekala W
Zientek H
Bartram CR
Burwinkel B
Source :
International journal of cancer [Int J Cancer] 2005 Nov 20; Vol. 117 (4), pp. 638-42.
Publication Year :
2005

Abstract

c-MYC is a multifaceted protein that regulates cell proliferation, differentiation and apoptosis. Its crucial role in diverse cancers has been demonstrated in several studies. Here, we analysed the influence of the rare c-MYC Asn11Ser polymorphism on familial breast cancer risk by performing a case-control study with a Polish (cases n = 349; controls n = 441) and a German (cases n = 356; controls n = 655) study population. All cases have been tested negative for mutations in the BRCA1 and BRCA2 genes. A joint analysis of the Polish and the German study population revealed a 54% increased risk for breast cancer associated with the heterozygous Asn11Ser variant (OR = 1.54, 95% CI 1.05-2.26, p = 0.028). The breast cancer risk associated with this genotype increases above the age of 50 years (OR = 2.24, 95% CI 1.20-4.21, p = 0.012). The wild-type amino acid Asn of this polymorphism is located in the N-terminal MYC transactivation domain and is highly conserved not only among most diverse species but also in the N-MYC homologue. Due to the pivotal role of c-MYC in diverse tumours, this variant might affect the genetic susceptibility of other cancers as well.<br /> (Copyright 2005 Wiley-Liss, Inc.)

Details

Language :
English
ISSN :
0020-7136
Volume :
117
Issue :
4
Database :
MEDLINE
Journal :
International journal of cancer
Publication Type :
Academic Journal
Accession number :
15929079
Full Text :
https://doi.org/10.1002/ijc.21225